DOCSLIB.ORG

Identification of Prekallikrein and High-Molecular-Weight Kininogen As a Complex in Human Plasma (Hageman Factor/Bradykinin Generation/Contact Activation) ROBERT J

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification of Prekallikrein and High-Molecular-Weight Kininogen As a Complex in Human Plasma (Hageman Factor/Bradykinin Generation/Contact Activation) ROBERT J Proc. Nati. Acad. Sci. USA Vol. 73, No. 11, pp. 4179-4183, November 1976 Immunology Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma (Hageman factor/bradykinin generation/contact activation) ROBERT J. MANDLE*, ROBERT W. COLMANt, AND ALLEN P. KAPLAN** * Allergic Diseases Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20014; and t The Coagulation Unit of the Hematology-Oncology Section, Department of Medicine, University of Pennsylvania, Philadelphia, Pa. 19104 Communicated by K. Frank Austen, August 19, 1976 ABSTRACT Prekallikrein and high-molecular-weight ki- (Fletcher trait) was a gift from Dr. C. Abildgaard (University ninogen were found associated in normal human plasma at a of California, Davis, Calif.). Kininogen-deficient plasma was molecular weight of 285,000, as assessed by gel filtration on obtained from Ms. Williams and was collected as described Sephadex G-200. The molecular weight of prekallikrein in plasma that is deficient in high-molecular-weight kininogen was (3). 115,000. This prekallikrein could be isolated at a molecular Preparation of Plasma Proteins. Fresh plasma used for the weight of 285,000 after plasma deficient in high-molecular- isolation of prekallikrein and HMW kininogen was collected weight kininogen was combined with plasma that is congeni- in 0.38% sodium citrate. Hexadimethrine bromide (3.6 mg) in tally deficient in prekallikrein. Addition of purified 125I-labeled 0.1 ml of 0.15 M saline was added for each 10 ml of blood prekallikrein and high-molecular-weight kininogen to the re- drawn. The tubes were then centrifuged at 900 X g for 20 min spective deficient plasma yielded a shift in the molecular weight of prekallikrein, and complex formation could be demonstrated at 40 and the plasma was separated with plastic pipettes. Plastic by incubating prekallikrein with high-molecular weight kini- columns and test tubes were used throughout the chromato- nogen. This study demonstrates that prekallikrein and high- graphic procedures to minimize contact activation of Hageman molecular-weight kininogen are physically associated in plasma factor and nonspecific adsorption to glass surfaces. Samples as a noncovalently linked complex and may therefore be ad- were concentrated by ultrafiltration (Amicon Corp., Lexington, sorbed together during surface activation of Hageman factor. Mass.) through a UM-10 membrane. The complex is disrupted when these proteins are isolated by Hageman Factor Fragments. Prealbumin fragments of ion exchange chromatography. Hageman factor were purified by chromatography of plasma Activation of Hageman factor upon a negatively charged sur- on QAE-Sephadex twice, Sephadex G-100, and SP-Sephadex, face initiates the intrinsic coagulation pathway, the fibrinolytic and elution from alkaline disc gels after electrophoresis as re- pathway, and the generation of the vasoactive peptide bra- ported (6). dykinin. Recent investigations from several laboratories have Prekallikrein. Two liters of fresh plasma were dialyzed shown that the proteins of the kinin-forming pathway, namely, against 0.003 M phosphate buffer (pH 8.3) and passed over a prekallikrein (1, 2) and high-molecular-weight (HMW) kini- 20 X 100 cm column of QAE-Sephadex equilibrated with the nogen (3-5), are both required for optimal activation and same buffer. The effluent, containing a mixture of proteins of function of Hageman factor. Since prekallikrein and HMW gamma globulin mobility, was then fractionated by sequential kininogen are intimately associated functionally, it appeared chromatography on SP-Sephadex and Sephadex G-150, as de- possible that they might be physically associated in plasma. In scribed (7), followed by passage over an immunoadsorbent this paper we demonstrate that prekallikrein and HMW kini- prepared with antisera to human IgG and ,B2 glycoprotein I. nogen circulate in plasma as a noncovalently linked complex. For preparation of the immunoadsorbent, 100 ml of sheep Formation of this complex was observed: (a) when prekalli- antiserum to human IgG and 132 glycoprotein I was made 45% krein-deficient plasma was combined with plasma deficient in ammonium sulfate and stirred at 24° for 1 hr. The mixture in HMW kininogen, (b) after prekallikrein-deficient plasma was centrifuged at 1200 X g for 90 min at 40, and the precipi- and plasma deficient in HMW kininogen were reconstituted tate was washed twice in 45% ammonium sulfate. The washed with prekallikrein and HMW kininogen, respectively, and (c) precipitate was dissolved in distilled water, dialyzed against when purified prekallikrein was incubated with HMW kini- three changes of 10 liters of 0.003 M phosphate buffer-0. 15 M nogen. NaCl (pH 7.5) for 24 hr at 40, and coupled to 250 ml of Seph- arose 4B by the cyanogen bromide method (8). The Sepharose MATERIALS AND METHODS was poured into a 5 X 20 cm plastic column, washed with one column volume of 1.0% ethanolamine, and then equilibrated Apoferritin and catalase (Calbiochem, San Diego, Calif.), blue in 0.003 M phosphate buffer-0.35 M NaCl (pH 8.0). Samples dextran, ovalbumin, ribonuclease A, and chymotrypsinogen were dialyzed against this buffer prior to application to the (Pharmacia Fine Chemicals, Inc., Piscataway, N.J.), chloramine immunoadsorbant. T (Matheson, Coleman and Bell Co., Norwood, Ohio), sodi- HMW Kininogen. HMW kininogen was isolated by chro- um[125I] iodide (New England Nuclear Co., Boston, Mass.), and matography of normal human plasma on QAE-Sephadex A-50, human transferrin (Sigma Chemical Co., St. Louis, Mo.) were ammonium sulfate precipitation, fractionation on SP-Sephadex, obtained as indicated. Plasma deficient in Hageman factor and and Sephadex G-200 gel filtration according to the method of containing 0.38% sodium citrate was obtained from Sera Tec Habal et al. (9). The preparation was quantitated functionally Biologicals, New Brunswick, N.J. Prekallikrein-deficient plasma by its ability to selectively correct the coagulation defect in Williams trait plasma as described (3). It was free of any de- Abbreviation: HMW kininogen, high-molecular-weight kininogen. tectable Hageman factor or prekallikrein. f To whom reprint requests should be addressed. The protein content of samples was approximated by ab- 4179 Downloaded by guest on September 27, 2021 4180 Immunology: Mandle et al. Proc. Natl. Acad. Sci. USA 73 (1976) sorbance at 280 nm with Al%m assumed to equal 10, or was determined by the Lowry method (10); the color reaction was 0.7 read at an optical density of 700 nm in a Beckman spectro- 0.6 photometer. Gel filtration on Sephadex G-150 (7), alkaline disc 0.5 E gel electrophoresis (11), and sodium dodecyl sulfate gel elec- 0.4 trophoresis (12) were performed as described. Prekallikrein was w radioiodinated by the Chloramine T method (13) using sodium 0.3 0.2 F:z [125I]iodide. The iodinated protein was immediately fraction- E ated on a 2 X 100 cm column of Sephadex G-50 equilibrated 0.1 8 in 0.003 M phosphate buffer-0.15 M NaCl (pH 8.0). The initial 0co peak of radioactivity was completely separated from the peak 'IC 0.7 0.6 of free iodine and contained over 99% trichloroacetic acid- I- precipitable counts. The 125I-labeled prekallikrein was mixed 0.5 0. with a 100-fold excess of nonradiolabeled prekallikrein in order 0.4 'S to assess binding to HMW kininogen. Radioactivity was de- 0.3 termined in a sodium iodide well scintillation counter (Nuclear 0.2 Chicago-Searle, Des Plaines, Ill., model 1185) with automatic 0.1 subtraction of background and an efficiency of 82%. Coagulation Assays. The partial thromboplastin time was 50 60 70 80 90 100 110 120 measured by the method of Proctor and Rapaport (14). Hage- TUBE NO. man factor, prekallikrein, and HMW kininogen were deter- FIG. 1. Sephadex G-200 gel filtration of normal human plasma mined by a modification of the procedure for determining (upper panel) and plasma deficient in Hageman factor (lower panel). partial thromboplastin time, with congenitally deficient plasma The column fractions were assayed for prekallikrein (A), HMW ki- (3). ninogen (o), and unactivated Hageman factor (0): Protein content Assays of Kinin-Forming Proteins. The proteolytic activity was estimated by the Lowry method and the color reaction was read of kallikrein was routinely measured by its ability to release at 700 nm (0). bradykinin from heat-inactivated plasma (11). Twenty-five the upper panel of Fig. 1, the prekallikrein and HMW kinino- microliters of kallikrein source were incubated with 0.2 ml of gen eluted in the same fractions, between the first and second substrate for 2 min of 370 and the bradykinin generated was protein peaks at an approximate molecular weight of 285,000, quantitated by bioassay as described (11). while unactivated Hageman factor was eluted between the Prekallikrein was determined by incubation of 25 ,l of second and third protein peaks at a molecular weight of proenzyme source with 25 ,ul of Hageman factor fragments (25 110,000-120,000. When plasma deficient in Hageman factor jig/ml) for 5 min at 370 and the kallikrein generated was de- was fractionated in an identical fashion (lower panel, Fig. 1), termined. prekallikrein and HMW kininogen were again found together Unactivated Hageman factor was assayed for its kinin-gen- at a molecular weight of 285,000. The elution position of pre- erating capacity by adding 10 ,l of sample to 200 ,g of plasma kallikrein and Hageman factor in the normal plasma chro- deficient in Hageman factor containing 0.9 mg/ml of EDTA. matogram was then confirmed, as assessed by their kinin- Fifty microliters of a suspension of kaolin in 0.15 M NaCl (10 generating ability. The location of each protein as assessed by mg/ml) were added, the mixture was incubated for 2 min at kinin generation was identical to its elution profile as assessed 370C and applied to the bioassay.
Load more

Recommended publications
  • A Novel Detection Method of Cleaved Plasma High-Molecular-Weight Kininogen Reveals Its Correlation with Alzheimer’S Pathology and Cognitive Impairment
    Alzheimer’s& Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 480-489 Blood-Based Biomarkers A novel detection method of cleaved plasma high-molecular-weight kininogen reveals its correlation with Alzheimer’s pathology and cognitive impairment Hitomi Yamamoto-Imotoa,b, Daria Zamolodchikova, Zu-Lin Chena, S. Lloyd Bournec, Syeda Rizvic, Pradeep Singha, Erin H. Norrisa, Frances Weis-Garciac, Sidney Stricklanda,* aPatricia and John Rosenwald Laboratory of Neurobiology and Genetics, The Rockefeller University, New York, NY, USA bResearch fellow of Japan Society for the Promotion of Science, Chiyoda-ku, Tokyo, Japan cAntibody and Bioresource Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA Abstract Introduction: Accumulation of b-amyloid is a pathological hallmark of Alzheimer’s disease (AD). b-Amyloid activates the plasma contact system leading to kallikrein-mediated cleavage of intact high-molecular-weight kininogen (HKi) to cleaved high-molecular-weight kininogen (HKc). Increased HKi cleavage is observed in plasma of AD patients and mouse models by Western blot. For potential diagnostic purposes, a more quantitative method that can measure HKc levels in plasma with high sensitivity and specificity is needed. Methods: HKi/c, HKi, and HKc monoclonal antibodies were screened from hybridomas using direct ELISA with a fluorescent substrate. Results: We generated monoclonal antibodies recognizing HKi or HKc specifically and developed sand- wich ELISAs that can quantitatively detect HKi and HKc levels in human. These new assays show that decreased HKi and increased HKc levels in AD plasma correlate with dementia and neuritic plaque scores. Discussion: High levels of plasma HKc could be used as an innovative biomarker for AD.
    [Show full text]
  • High Molecular Weight Kininogen Contributes to Early Mortality and Kidney Dysfunction in a Mouse Model of Sickle Cell Disease
    DR ERICA SPARKENBAUGH (Orcid ID : 0000-0002-5529-7847) DR NIGEL KEY (Orcid ID : 0000-0002-8930-4304) Article type : Original Article High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease. Erica M Sparkenbaugh1, Malgorzata Kasztan2, Michael W Henderson1, Patrick Ellsworth1, Parker Ross Davis2, Kathryn J Wilson1, Brandi Reeves1, Nigel S Key1,5, Sidney Strickland3, Keith McCrae4, David M. Pollock2, Rafal Pawlinski1* 1UNC Blood Research Center, Division of Hematology & Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; 2Section of Cardio-Renal Physiology and Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; 3Patricia and John Rosenwald Laboratory of Neurobiology and Genetics, The Rockefeller University, New York, NY; 4Taussig Cancer Institute, Department of Hematology Oncology, Cleveland Clinic, Cleveland, OH; and 5Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC. *Address for correspondence Rafal Pawlinski 8008B Mary Ellen Jones Bldg, CB 7035 This article has been accepted for publication and undergone full peer review but has not been throughAccepted Article the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/JTH.14972 This article is protected by copyright. All rights reserved 116 Manning Drive Chapel Hill, NC 27599-7025 Ph: 919-843-8387 Fax: 919-843-4896 Email: [email protected] Word Counts Abstract: 179 Main Text: 3691 Figures: Main manuscript has 6 figures, 2 tables; supplement has 4 tables and 3 figures.
    [Show full text]
  • T-Kininogen 1/2 (F-12): Sc-103886
    SANTA CRUZ BIOTECHNOLOGY, INC. T-kininogen 1/2 (F-12): sc-103886 The Power to Question BACKGROUND SOURCE In rats, four types of kininogens are produced, two of which are classical T-kininogen 1/2 (F-12) is an affinity purified goat polyclonal antibody raised high and low molecular weight kininogens and two of which are low molec- against a peptide mapping within an internal region of T-kininogen 2 of rat ular weight-like kininogens, designated T-kininogen 1 and T-kininogen 2. origin. T-kininogen 1 and T-kininogen 2 are 430 amino acid secreted rat proteins that each contain three cystatin domains and have nearly identical functions. PRODUCT Existing in plasma, both T-kininogen 1 and T-kininogen 2 are glycoproteins Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide that act as thiol protease inhibitors and also play a role in blood coagulation, and 0.1% gelatin. specifically by helping to optimally position blood coagulation factors. Additionally, T-kininogen 1 and T-kininogen 2 act as precursors of the active Blocking peptide available for competition studies, sc-103886 P, (100 µg peptide Bradykinin and, as such, effect vascular permeability, hypotension peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA). and smooth muscle contraction. APPLICATIONS REFERENCES T-kininogen 1/2 (F-12) is recommended for detection of full length and heavy 1. Furuto-Kato, S., Matsumoto, A., Kitamura, N. and Nakanishi, S. 1985. chain of T-kininogen 1 and 2 of rat origin by Western Blotting (starting dilu- Primary structures of the mRNAs encoding the rat precursors for tion 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilu- bradykinin and T-kinin.
    [Show full text]
  • Activation of the Plasma Kallikrein-Kinin System in Respiratory Distress Syndrome
    003 I-3998/92/3204-043 l$03.00/0 PEDIATRIC RESEARCH Vol. 32. No. 4. 1992 Copyright O 1992 International Pediatric Research Foundation. Inc. Printed in U.S.A. Activation of the Plasma Kallikrein-Kinin System in Respiratory Distress Syndrome OLA D. SAUGSTAD, LAILA BUP, HARALD T. JOHANSEN, OLAV RPISE, AND ANSGAR 0. AASEN Department of Pediatrics and Pediatric Research [O.D.S.].Institute for Surgical Research. University of Oslo [L.B.. A.O.A.], Rikshospitalet, N-0027 Oslo 1, Department of Surgery [O.R.],Oslo City Hospital Ullev~il University Hospital, N-0407 Oslo 4. Department of Pharmacology [H. T.J.],Institute of Pharmacy, University of Oslo. N-0316 Oslo 3, Norway ABSTRAm. Components of the plasma kallikrein-kinin proteins that interact in a complicated way. When activated, the and fibrinolytic systems together with antithrombin 111 contact factors plasma prekallikrein, FXII, and factor XI are were measured the first days postpartum in 13 premature converted to serine proteases that are capable of activating the babies with severe respiratory distress syndrome (RDS). complement, fibrinolytic, coagulation, and kallikrein-kinin sys- Seven of the patients received a single dose of porcine tems (7-9). Inhibitors regulate and control the activation of the surfactant (Curosurf) as rescue treatment. Nine premature cascades. C1-inhibitor is the most important inhibitor of the babies without lung disease or any other complicating contact system (10). It exerts its regulatory role by inhibiting disease served as controls. There were no differences in activated FXII, FXII fragment, and plasma kallikrein (10). In prekallikrein values between surfactant treated and non- addition, az-macroglobulin and a,-protease inhibitor inhibit treated RDS babies during the first 4 d postpartum.
    [Show full text]
  • High Molecular Weight Kininogen Is an Inhibitor of Platelet Calpain
    High molecular weight kininogen is an inhibitor of platelet calpain. A H Schmaier, … , D Schutsky, R W Colman J Clin Invest. 1986;77(5):1565-1573. https://doi.org/10.1172/JCI112472. Research Article Recent studies from our laboratory indicate that a high concentration of platelet-derived calcium-activated cysteine protease (calpain) can cleave high molecular weight kininogen (HMWK). On immunodiffusion and immunoblot, antiserum directed to the heavy chain of HMWK showed immunochemical identity with alpha-cysteine protease inhibitor--a major plasma inhibitor of tissue calpains. Studies were then initiated to determine whether purified or plasma HMWK was also an inhibitor of platelet calpain. Purified alpha-cysteine protease inhibitor, alpha-2-macroglobulin, as well as purified heavy chain of HMWK or HMWK itself inhibited purified platelet calpain. Kinetic analysis revealed that HMWK inhibited platelet calpain noncompetitively (Ki approximately equal to 5 nM). Incubation of platelet calpain with HMWK, alpha-2- macroglobulin, purified heavy chain of HMWK, or purified alpha-cysteine protease inhibitor under similar conditions resulted in an IC50 of 36, 500, 700, and 1,700 nM, respectively. The contribution of these proteins in plasma towards the inhibition of platelet calpain was investigated next. Normal plasma contained a protein that conferred a five to sixfold greater IC50 of purified platelet calpain than plasma deficient in either HMWK or total kininogen. Reconstitution of total kininogen deficient plasma with purified HMWK to normal levels (0.67 microM) completely corrected the subnormal inhibitory activity. However, reconstitution of HMWK deficient plasma to normal levels of low molecular weight kininogen (2.4 microM) did not fully correct the subnormal calpain inhibitory capacity […] Find the latest version: https://jci.me/112472/pdf High Molecular Weight Kininogen Is an Inhibitor of Platelet Calpain Alvin H.
    [Show full text]
  • The Characteristic Normalization of the Severely Prolonged Aptt Following Increased Preincubation Time Is Due to Autoactivation of Factor XII
    Thrombosis Research 105 (2002) 463–470 Regular Article Prekallikrein deficiency: The characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII Lars M. Asmis*, Irmela Sulzer, Miha Furlan, Bernhard La¨mmle Central Hematology Laboratory, University of Bern, Inselspital, Bern CH 3010, Switzerland Received 8 November 2001; received in revised form 14 December 2001; accepted 28 January 2002 Accepting Editor: J. Meier Abstract Hereditary plasma prekallikrein (PK) deficiency was diagnosed in a 71-year-old man with an 8-year history of osteomyelofibrosis. PK deficiency was suspected in view of a severely prolonged activated partial thromboplastin time (aPTT) that nearly normalized following prolonged preincubation (10 min) of patient plasma with kaolin–inosithin reagent. Hereditary PK deficiency was demonstrated by very low PK values in the propositus (PK clotting activity 5%, PK amidolytic activity 5%, PK antigen 2% of normal plasma, respectively) and half normal PK values in his children. Normalization of a severely increased aPTT ( > 120 s) after prolonged preincubation with aPTT reagent occurred in plasma deficient in PK but not in plasma deficient in factor XII (FXII), high-molecular-weight kininogen (HK), factor XI (FXI), factor IX, factor VIII, Passovoy trait plasma or plasma containing lupus anticoagulant. Autoactivation of FXII in PK-deficient plasma in the presence of kaolin paralleled the normalization of aPTT. Addition of OT-2, a monoclonal antibody inhibiting activated FXII, prevented the normalization of aPTT. We conclude that the normalization of a severely prolonged aPTT upon increased preincubation time (PIT), characteristic of PK deficiency, is due to FXII autoactivation.
    [Show full text]
  • The Role of the Plasminogen Activation System in Angioedema: Novel Insights on the Pathogenesis
    Journal of Clinical Medicine Review The Role of the Plasminogen Activation System in Angioedema: Novel Insights on the Pathogenesis Filomena Napolitano and Nunzia Montuori * Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, 80135 Naples, Italy; fi[email protected] * Correspondence: [email protected]; Tel.: +39-0817463309 Abstract: The main physiological functions of plasmin, the active form of its proenzyme plasminogen, are blood clot fibrinolysis and restoration of normal blood flow. The plasminogen activation (PA) system includes urokinase-type plasminogen activator (uPA), tissue-type PA (tPA), and two types of plasminogen activator inhibitors (PAI-1 and PAI-2). In addition to the regulation of fibrinolysis, the PA system plays an important role in other biological processes, which include degradation of extracellular matrix such as embryogenesis, cell migration, tissue remodeling, wound healing, angiogenesis, inflammation, and immune response. Recently, the link between PA system and angioedema has been a subject of scientific debate. Angioedema is defined as localized and self- limiting edema of subcutaneous and submucosal tissues, mediated by bradykinin and mast cell mediators. Different forms of angioedema are linked to uncontrolled activation of coagulation and fibrinolysis systems. Moreover, plasmin itself can induce a potentiation of bradykinin production with consequent swelling episodes. The number of studies investigating the PA system involvement in angioedema has grown in recent years, highlighting its relevance in etiopathogenesis. In this review, we present the components and diverse functions of the PA system in physiology and its importance in angioedema pathogenesis. Citation: Napolitano, F.; Montuori, Keywords: angioedema; fibrinolysis; plasmin; uPAR; tPA N.
    [Show full text]
  • The Molecular Basis of Blood Coagulation Review
    Cell, Vol. 53, 505-518, May 20, 1988, Copyright 0 1988 by Cell Press The Molecular Basis Review of Blood Coagulation Bruce Furie and Barbara C. Furie into the fibrin polymer. The clot, formed after tissue injury, Center for Hemostasis and Thrombosis Research is composed of activated platelets and fibrin. The clot Division of Hematology/Oncology mechanically impedes the flow of blood from the injured Departments of Medicine and Biochemistry vessel and minimizes blood loss from the wound. Once a New England Medical Center stable clot has formed, wound healing ensues. The clot is and Tufts University School of Medicine gradually dissolved by enzymes of the fibrinolytic system. Boston, Massachusetts 02111 Blood coagulation may be initiated through either the in- trinsic pathway, where all of the protein components are present in blood, or the extrinsic pathway, where the cell- Overview membrane protein tissue factor plays a critical role. Initia- tion of the intrinsic pathway of blood coagulation involves Blood coagulation is a host defense system that assists in the activation of factor XII to factor Xlla (see Figure lA), maintaining the integrity of the closed, high-pressure a reaction that is promoted by certain surfaces such as mammalian circulatory system after blood vessel injury. glass or collagen. Although kallikrein is capable of factor After initiation of clotting, the sequential activation of cer- XII activation, the particular protease involved in factor XII tain plasma proenzymes to their enzyme forms proceeds activation physiologically is unknown. The collagen that through either the intrinsic or extrinsic pathway of blood becomes exposed in the subendothelium after vessel coagulation (Figure 1A) (Davie and Fiatnoff, 1964; Mac- damage may provide the negatively charged surface re- Farlane, 1964).
    [Show full text]
  • Anti-Prekallikrein Heavy Chain Antibody [13G11] (ARG54564)
    Product datasheet [email protected] ARG54564 Package: 50 μg anti-Prekallikrein Heavy Chain antibody [13G11] Store at: -20°C Summary Product Description Mouse Monoclonal antibody [13G11] recognizes Prekallikrein Heavy Chain Tested Reactivity Hu Tested Application ELISA, IHC, WB Specificity This antibody specifically recognizes in human plasma two variants (88 kDa and 85 kDa) of prekallikrein and its activation products kallikrein (88 kDa and 85 kDa), the complexes formed by kallikrein with its endogenous inhibitors C1 inhibitor, alpha-2-macroglobulin and antithrombin III, and 45 kDa prekallikrein/kallikrein fragment(s). It also recognizes prekallikrein and its activation products in chimpanzee, rhesus, and baboon plasmas. The epitope for this antibody, located on the prekallikrein/kallikrein heavy chain, is involved in the interaction between prekallikrein and factor XIIa. This antibody inhibits prekallikrein activation in human and rhesus plasmas by approximately 60-80% and 55%, respectively. This antibody does not cross-react with tissue kallikrein. Host Mouse Clonality Monoclonal Clone 13G11 Isotype IgG1 Target Name Prekallikrein Heavy Chain Antigen Species Human Immunogen Human plasma prekallikrein. Conjugation Un-conjugated Alternate Names Williams-Fitzgerald-Flaujeac factor; Kallidin II; High molecular weight kininogen; KNG; Fitzgerald factor; Alpha-2-thiol proteinase inhibitor; BDK; BK; Kininogen-1; HMWK; Kallidin I; Ile-Ser-Bradykinin Application Instructions Application Note This antibody may be used in ELISA and Western blots to identify/quantitate prekallikrein and its activation products in plasmas of humans, chimpanzees, rhesus monkeys, and baboons. Other applications are under investigation. NOTE: Prekallikrein activation may occur with repeated freezing/thawing (3x or more) of plasma samples obtained from humans or other primates.
    [Show full text]
  • Human KNG1 / BDK / Kininogen-1 Protein (His Tag)
    Human KNG1 / BDK / Kininogen-1 Protein (His Tag) Catalog Number: 10529-H08H General Information SDS-PAGE: Gene Name Synonym: BDK; BK; KNG Protein Construction: A DNA sequence encoding the human KNG1 isoform 1 (NP_001095886.1) (Gln 19-Ser 644) was fused with a polyhistidine tag at the C-terminus, and a signal peptide at the N-terminus. Source: Human Expression Host: HEK293 Cells QC Testing Purity: > 85 % as determined by SDS-PAGE Bio Activity： Protein Description Measured by its ability to inhibit papain cleavage of a fluorogenic Kininogen-1, also known as high molecular weight kininogen, williams- peptide substrate Z-FR-AMC, R&D Systems, Catalog # ES009 . The IC50 Fitzgerald-Flaujeac factor, Alpha-2-thiol proteinase inhibitor, Fitzgerald value is < 7 nM . factor, KNG1 and BDK, is a secreted protein which contains threecystatin domains. Kininogen-1 / KNG1 is a protein from the blood coagulation Endotoxin: system as well as the kinin-kallikrein system. It is a protein that adsorbs to the surface of biomaterials that come in contact with blood. Kininogen-1 / < 1.0 EU per μg of the protein as determined by the LAL method KNG1 circulates throughout the blood and quickly adsorbs to the material surfaces. Kininogen-1 / KNG1 is one of the early participants of the intrinsic Stability: pathway of coagulation, together with Factor XII (Hageman factor) and Samples are stable for up to twelve months from date of receipt at -70 ℃ prekallikrein. Kininogen-1 / KNG1 is one of thekininogens, a class of proteins. As with many other coagulation proteins, the protein was initially Predicted N terminal: Gln 19 named after the patients in whom deficiency was first observed.
    [Show full text]
  • Prekallikrein Deficiency
    Prekallikrein deficiency Description Prekallikrein deficiency is a blood condition that usually causes no health problems. In people with this condition, blood tests show a prolonged activated partial thromboplastin time (PTT), a result that is typically associated with bleeding problems; however, bleeding problems generally do not occur in prekallikrein deficiency. The condition is usually discovered when blood tests are done for other reasons. A few people with prekallikrein deficiency have experienced health problems related to blood clotting such as heart attack, stroke, a clot in the deep veins of the arms or legs ( deep vein thrombosis), nosebleeds, or excessive bleeding after surgery. However, these are common problems in the general population, and most affected individuals have other risk factors for developing them, so it is unclear whether their occurrence is related to prekallikrein deficiency. Frequency The prevalence of prekallikrein deficiency is unknown. Approximately 80 affected individuals in about 30 families have been described in the medical literature. Because prekallikrein deficiency usually does not cause any symptoms, researchers suspect that most people with the condition are never diagnosed. Causes Prekallikrein deficiency is caused by mutations in the KLKB1 gene, which provides instructions for making a protein called prekallikrein. This protein, when converted to an active form called plasma kallikrein in the blood, is involved in the early stages of blood clotting. Plasma kallikrein plays a role in a process called the intrinsic coagulation pathway (also called the contact activation pathway). This pathway turns on (activates) proteins that are needed later in the clotting process. Blood clots protect the body after an injury by sealing off damaged blood vessels and preventing further blood loss.
    [Show full text]
  • Plasma Prekallikrein Determination of Prekallikrein in Plasma with a Chromogenic Substrate
    Plasma Prekallikrein Determination of prekallikrein in plasma with a chromogenic substrate Measurement Principle The activation of plasma prekallikrein is mediated by the Hageman factor on negatively charged surfaces and in presence of HMW kininogen. A number of methods have been described for the activation of prekallikrein. This method is related to the use of human FXIIa (Hageman factor) acting as prekallikrein activator. However, the assay should be validated with respect to the particular activator used. Following the activation, the plasma kallikrein formed catalyses the hydrolysis of p-nitroaniline (pNA) from the chromogenic substrate H-D-Pro-Phe-Arg-pNA (CS-31(02)). The rate at which pNA is released is measured photometrically at 405 nm. This can be followed on a recorder (initial rate method) or read after stopping the reaction with acetic acid (acid stopped method). The concentration of prekallikrein is calculated by using standards prepared from normal plasma. Contact activation F XII FXIIa FXIIa + HMW kininogen Prekallikrein Kallikrein Kallikrein H-D-Pro-Phe-Arg-pNA + H2O H-D-Pro-Phe-Arg-OH + pNA Reagents 1. Chromogenic substrate e.g. CS-31(02), 25 mg; art.no.: 229031 Reconstitute with 20 mL of distilled water. 2. Human Factor XIIa - Prekallikrein Activator, 100 ng; art.no.: EZ012A Reconstitute with 5 mL of Tris-buffer (3). 3. Tris-Buffer pH 7.8; art.no.: AR103A (10 mL) 4. Calibration Plasma; art.no.: CCNRP-05 (25x0.5 mL), CCNRP-10 (25x1.0 mL) 5. Acetic acid, 20% or citric acid 2%, used in the acid-stopped method only. Specimen collection Blood (9 vol) is mixed with 0.1 mol/L sodium citrate (1 vol) and centrifuged at 2000 x g for 20 minutes at 15-25°C.
    [Show full text]